Starting the End-of-Life Conversation

The phase 3 ZEST trial discovered that, with low ctDNA at baseline, the recurrence-free interval is longer for patients with triple-negative breast cancer.

Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.

Niraparib/dostarlimab with platinum-therapy met its PFS end point in patients with advanced ovarian cancer in the phase 3 FIRST-ENGOT-OV44 trial.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Nab-paclitaxel elicited a pathologic complete response rate of 66.3% compared with 57.6% with docetaxel plus carboplatin, the phase 3 HELEN-006 trial found.

Results from a phase 1a trial showed that NX-5948 yielded an overall response rate of 77.8% in later lines of treatment for patients with WM.